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Femoropopliteal Arterial Disease Treated
with the IN.PACT Drug-Coated Balloon in
the IN.PACT SFA Randomized Controlled
Trial: A Post Hoc AnalysisMaureen P. Kohi, MD, Marianne Brodmann, MD, Thomas Zeller, MD, PhD,
Antonio Micari, MD, Iris Baumgartner, MD, Hong Wang, MD, MPH,
Bridget Wall, PhD, and Mahmood K. Razavi, MDABSTRACT
Purpose: To evaluate sex-related disparities in long-term outcomes of patients with peripheral artery disease (PAD) treated with
IN.PACT drug-coated balloon (DCB) or percutaneous transluminal angioplasty (PTA).
Materials and Methods: A post hoc analysis of the IN.PACT SFA trial was performed. Participants with Rutherford Clinical
Classification 2–4 PAD and femoropopliteal artery lesions up to 18 cm long were randomly assigned to treatment with DCB (n ¼ 220) or
PTA (n ¼ 111). Effectiveness outcomes were evaluated, including 36-month primary patency (freedom from binary restenosis and
freedom from clinically driven [CD] target lesion revascularization [TLR]).
Results: In the DCB group, women were significantly older (69.4 y ± 9.9) than men (66.4 y ± 9.1; P ¼ .025). Mean reference vessel
diameter (RVD) was significantly smaller in women (4.4 mm ± 0.68) compared with men (4.8 mm ± 0.89, P < .001). Primary patency
was 65.4% in women and 71.8% in men (P ¼ .302). Freedom from CD-TLR was 81.1% in women and 86.4% in men (P ¼ .285).
Women treated with PTAwere older (70.4 y ± 8.3) than men (66.9 y ± 9.5; P ¼ .063). Mean RVD was significantly smaller in women
(4.2 mm ± 0.77) compared with men (4.9 mm ± 0.77, P < .001). Primary patency was 42.3% in women and 46.7% in men (P ¼ .551).
Freedom from CD-TLR was 59.4% in women and 75.5% in men (P ¼ .109). No significant differences were noted in safety and
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Volume 31 ▪ Number 9 ▪ September ▪ 2020 1411Conclusions: In both groups, women were older and had smaller vessels. Particularly in the PTA group, women had worse clinical
outcomes, though not reaching statistical significance. Further evaluation is necessary to understand the disparate nature of disease
progression and outcomes following endovascular treatment in women compared with men.
ABBREVIATIONS
CD ¼ clinically driven, DCB ¼ drug-coated balloon, PAD ¼ peripheral artery disease, RVD ¼ reference vessel diameter, TLR ¼ target
lesion revascularization, TVR ¼ target vessel revascularizationPeripheral artery disease (PAD) affects > 200 million peo-
ple worldwide and is now recognized as a cardiovascular
pandemic (1). Recent studies have demonstrated that the
prevalence of PAD is likely higher in women than in men,
and women with PAD are more likely to present at an older
age with more advanced disease (2,3). Furthermore, women
with PAD have both higher functional impairment and faster
functional decline than women without PAD (2). Sex-related
differences have also been reported in the outcomes of PAD
treatment with standard percutaneous transluminal angio-
plasty (PTA), where women have demonstrated a higher 12-
month reintervention rate compared with men (4). Recent
randomized trials have shown superior outcomes with
paclitaxel drug-coated balloons (DCBs) over PTA in the
treatment of patients with femoropopliteal PAD (5–10). The
IN.PACT SFA trial demonstrated superiority of DCB
compared with PTA in both men and women (6). The pur-
pose of this post hoc analysis was to examine sex-related
disparities in the long-term outcomes of patients with PAD
treated with DCB or PTA.MATERIALS AND METHODS
IN.PACT SFAwas a prospective, multicenter, multinational,
randomized, single-blind trial evaluating safety and effec-
tiveness of a paclitaxel DCB (IN.PACTAdmiral; Medtronic,
Dublin, Ireland) versus PTA in the treatment of patients with
symptomatic superficial femoral artery and/or proximal
popliteal artery disease. As this was an investigational de-
vice exemption trial, end points and definitions were
determined in concert with the US Food and Drug Admin-
istration. Clinical sites are listed in Table E1 (available
online on the article’s Supplemental Material page at
www.jvir.org). Methods and results through 5 years have
been reported (5–7,11).
IN.PACT SFA I and IN.PACT SFA II were evaluated
together for these results. The trials are registered at
Clinical Trials.gov: Randomized Trial of IN.PACT Ad-
miral Drug Coated Balloon vs Standard PTA for the
Treatment of SFA and Proximal Popliteal Arterial Disease
(IN.PACT SFA I); https://clinicaltrials.gov/ct2/show/
NCT01175850; ClinicalTrials.gov Identifier:
NCT01175850; IN.PACT Admiral Drug-Coated Balloon
vs. Standard Balloon Angioplasty for the Treatment of
Superficial Femoral Artery (SFA) and Proximal PoplitealArtery (PPA) (IN.PACT SFA II); https://clinicaltrials.gov/
ct2/show/NCT01566461; ClinicalTrials.gov Identifier:
NCT01566461.Patient Population and Treatment
Eligible patients had moderate to severe intermittent claudi-
cation or ischemic rest pain (Rutherford Clinical Classification
2–4); stenosis of 70%–99% with lesion lengths between 4 cm
and 18 cm or a complete occlusion with lengths of  10 cm
involving the superficial femoral and/or proximal popliteal
arteries; and were required to have successful predilation of
the lesion before enrollment (Table E2 [available online on
the article’s Supplemental Material page at www.jvir.org]). A
total of 331 participants were randomly assigned in a 2:1
fashion into a DCB or a PTA group and stratified by site (Fig
1 and Fig E1 [available online on the article’s Supplemental
Material page at www.jvir.org]).Study End Points
Primary patency was defined as freedom from clinically
driven (CD) target lesion revascularization (TLR) and
freedom from binary restenosis (duplex ultrasonography
peak systolic velocity ratio  2.4) and was analyzed through
36 months. CD-TLR was defined as reintervention at the
target lesion because of symptoms or a decrease in ankle-
brachial index by  20% or > 0.15 compared with base-
line ankle-brachial index after the procedure. The primary
composite safety end point was freedom from device- and
procedure-related death through 30 days and freedom from
major target limb amputation and CD target vessel revas-
cularization (TVR) through 36 months. A blinded inde-
pendent Clinical Events Committee reviewed and
adjudicated all major adverse events through the 36-month
follow-up period. Blinded independent core laboratories
(VasCore, Boston, Massachusetts [duplex ultrasonography]
and SynvaCor, Springfield, Illinois [angiography]) analyzed
all procedural and follow-up images through 36 months.Statistical Analysis
In this post hoc analysis of the IN.PACT SFA trial, participant
demographics, lesion characteristics, procedural details, and
rates of primary patency, freedom from CD-TLR, and safety
through 3 years were compared based on sex. The DCB arm
Figure 1. Follow-up of participants treated with a DCB through 3 years.
Figure 2. Primary patency and freedom from CD-TLR through 3 years by sex of participants treated with DCB. (a) Primary patency by
Kaplan-Meier estimate was not statistically significantly different between male and female participants treated with DCB through 36 months
(log-rank test, P ¼ .302). (b) Freedom from CD-TLR by Kaplan-Meier estimate was not statistically significantly different between male and
female participants treated with DCB through 36 months (log-rank test, P ¼ .285). An independent and blinded Clinical Events Committee
adjudicated all TLR events, and independent and blinded core laboratories reviewed all ultrasound and angiographic images.
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Table 1. End Points through 3 Years of Participants Treated with DCB
End Points through 3 Years Male DCB
(n ¼ 143 participants)
Female DCB
(n ¼ 77 participants)
P Value*
Primary safety composite end point†—freedom from: 83.6% (107/128) 76.8% (53/69) .257
Device- and procedure-related death through 30 days 0.0% (0/143) 0.0% (0/76) > .999
Major target limb amputation within 1,080 days 0.0% (0/128) 0.0% (0/69) > .999
CD-TVR within 1,080 days 16.4% (21/128) 23.2% (16/69) .257
Death (all-cause) within 30 days 0.0% (0/143) 0.0% (0/76) > .999
Cumulative Complications within 1,080 Days
MAE composite‡ 25.8% (33/128) 31.9% (22/69) .406
Death (all-cause) 10.2% (13/128) 11.6% (8/69) .810
CD-TVR 16.4% (21/128) 23.2% (16/69) .257
Major target limb amputation 0.0% (0/128) 0.0% (0/69) > .999
Thrombosis at target lesion site§ 1.6% (2/128) 2.9% (2/69) .613
CD-TLR 13.3% (17/128) 18.8% (13/69) .306
Any TVR 17.2% (22/128) 23.2% (16/69) .346
Any TLR 14.8% (19/128) 18.8% (13/69) .544
Other Major Secondary End Points at 36 Months
Time to first CD-TLR within 1,080 days (d) 575.5 ± 308.5 (17) 500.4 ± 238.0 (13) .473
Primary sustained clinical improvementk 72.5% (79/109) 61.4% (35/57) .161
Secondary sustained clinical improvement¶ 87.4% (90/103) 81.1% (43/53) .343
Change in quality of life from baseline by EQ-5D Index 0.0932 ± 0.2021 (103) 0.0637 ± 0.2757 (53) .492
Change in walking distance from baseline by 6MWT (m) 13.4 ± 115.1 (38) 1.4 ± 131.4 (16) .681
Walking impairment by WIQ (%) 74.8 ± 32.6 (104) 66.2 ± 36.7 (54) .136
Change in ABI/TBI# from baseline to 36 months (ratio mm Hg) 0.125 ± 0.248 (97) 0.153 ± 0.253 (47) .527
Nights in hospital due to index lesion 1.2 ± 1.4 (143) 2.3 ± 4.2 (76) .026
NoteValues are reported as % (n/N) or mean ± SD (N). All events were adjudicated by the independent Clinical Events Committee,
and all duplex ultrasound and angiographic measures were made by the independent core laboratories; all other data were site-
reported.
6MWT ¼ 6-minute walk test; ABI ¼ ankle-brachial index; CD ¼ clinically driven; DCB ¼ drug-coated balloon; EQ-5D ¼ EuroQoL
5-dimension health-related quality-of-life questionnaire; MAE ¼ major adverse event; PTA ¼ percutaneous transluminal angioplasty;
TBI ¼ toe-brachial index; TLR ¼ target lesion revascularization; TVR ¼ target vessel revascularization; WIQ ¼ Walking Impairment
Questionnaire.
*P values are based on Fisher exact test or t test for superiority with significance level of .05.
†Defined as 30-day freedom from device- and procedure-related death and major target limb amputation and 36-month freedom from
CD-TVR.
‡Composite of death, CD-TVR, major target limb amputation, and thrombosis at target lesion site.
§Defined as occlusion because of thrombus formation, confirmed by sudden onset of symptoms and documented by duplex ultra-
sonography and angiography.
kDefined as sustained upward shift of at least 1 category on Rutherford Clinical Classification scale compared with baseline, freedom
from major target limb amputation, and freedom from TVR.
¶Defined as sustained upward shift of at least 1 category on Rutherford Clinical Classification scale compared with baseline, and
freedom from major target limb amputation (participants could have had TVR).
#TBI was not measured in IN.PACT SFA I phase.
Volume 31 ▪ Number 9 ▪ September ▪ 2020 1413included 143 men and 77 women (Fig 1); the PTA arm
included 75 men and 36 women (Fig E1 [available online on
the article’s Supplemental Material page at www.jvir.org]).
Participant-level summaries were used for baseline de-
mographics, clinical characteristics, and outcome analyses;
lesion-level summaries were used for lesion characteristics.
Continuous variables were displayed as mean ± SD; dichoto-
mous and categorical variables were presented as counts and
percentages. For baseline characteristics, continuous variables
were compared by Student t tests; dichotomous and categorical
variables were compared by Fisher exact test and Cochran-Mantel-Haenszel modified ridit scores, respectively. Outcome
analyses were performed at the participant level. The Kaplan-
Meier method was used to evaluate time-to-event data for pri-
mary patency and freedom from CD-TLR over the 36-month
follow-up period. The difference in the survival curves be-
tween comparison groups was assessed using the log-rank test.
For other outcomes, Fisher exact test was used to compare bi-
nary outcomes, and the Student t test was used for continuous
outcomes. For event rates that were expressed as a proportion,
the number of participants with an event within 1,080 days was
the numerator, and the total number of participants with an
Table 2. Multivariable Analysis of Predictors of Outcomes through 3 Years
Predictors Hazard Ratio [95% CI] P Value
Predictors of loss of primary patency—women treated with DCB
Baseline TASC lesion—C/D vs A/B 7.30 [2.77, 19.19] < .001
Previous limb amputation, yes/no 22.20 [1.80, 273.63] .016
SFA proximal/mid vs distal 5.87 [0.98, 35.16] .053
Predictors of loss of primary patency—men treated with DCB
Lesion length (per cm)* 1.28 [1.09, 1.50] .002
Total treatment balloon length (per cm)* 0.98 [0.97, 1.00] .021
SFA proximal/mid vs distal 2.82 [0.98, 8.06] .054
Age (y)* 0.97 [0.93, 1.01] .098
Predictors of CD-TLR—women treated with DCB
Severe calcification, yes/no 4.33 [1.07, 17.48] .039
Previous ipsilateral revascularization (SFA/PPA), yes/no 5.71 [1.26, 25.81] .024
Hyperlipidemia, yes/no 0.14 [0.03, 0.66] .013
Insulin-dependent diabetes mellitus (yes/no) 6.96 [1.65, 29.36] .008
Reference vessel diameter (per mm)* 0.323 [0.09, 1.19] .089
Previous limb amputation, yes/no 12.39 [0.99, 155.54] .051
Predictors of CD-TLR—men treated with DCB
Reference vessel diameter (per mm)* 0.46 [0.25,0.84] .012
BMI (per kg/m2)* 1.12 [1.01, 1.24] .026
Note–Multiple Cox proportional hazards regression of participants treated with DCB.
BMI ¼ body mass index; CD ¼ clinically driven; CI ¼ confidence interval; DCB ¼ drug-coated balloon; PPA ¼ proximal popliteal artery;
SFA ¼ superficial femoral artery; TASC ¼ TransAtlantic Inter-Society Consensus for the Management of Peripheral Arterial Disease;
TLR ¼ target lesion revascularization.
*For continuous variables, the comparative direction is incremental for these measured characteristics.
1414 ▪ Outcomes of IN.PACT SFA Trial Through 3 Years by Sex Kohi et al ▪ JVIRevent or at least 1,050 days of clinical follow-up was the de-
nominator. The level of statistical significance was set at P< .05
with no correction for multiple comparisons. For functional
assessment of clinical characteristics at 36 months, participants
were required to have data at both baseline and 36 months to
assess any changes from baseline. To identify predictive factors
for revascularization and loss of patency separately for men andFigure 3. Primary patency and freedom from CD-TLR through 3 year
Kaplan-Meier estimate was not statistically significantly different between
(log-rank test, P ¼ .551). (b) Freedom from CD-TLR by Kaplan-Meier esti
female participants treated with PTA through 36 months (log-rank test,
adjudicated all TLR events, and independent and blinded core laboratorwomen treated with DCB, a multivariable analysis was per-
formed using a Cox proportional hazard model; identical
baseline covariates were used. To identify the predictive factors
for primary patency and CD-TLR in each subgroup, univariate
analyses followed by a stepwise multivariable Cox regression
model were employed. Variables were allowed to enter the
model using an entry criterion of 0.2 and stay in the models by sex of participants treated with PTA. (a) Primary patency by
male and female participants treated with PTA through 36months
mate was not statistically significantly different between male and
P ¼ .109). An independent and blinded Clinical Events Committee
ies reviewed all ultrasound and angiographic images.
Table 3. End Points through 3 Years of Participants Treated with PTA
End Points through 3 Years Male PTA
(n ¼ 75 participants)
Female PTA
(n ¼ 36 participants)
P Value*
Primary safety composite end point†—freedom from: 70.0% (49/70) 51.5% (17/33) .081
Device- and procedure-related death through 30 days 0.0% (0/75) 0.0% (0/36) > .999
Major target limb amputation within 1,080 days 0.0% (0/70) 0.0% (0/33) > .999
CD-TVR within 1,080 days 30.0% (21/70) 48.5% (16/33) .081
Death (all-cause) within 30 days 0.0% (0/75) 0.0% (0/36) > .999
Cumulative Complications within 1,080 Days
MAE composite‡ 31.4% (22/70) 51.5% (17/33) .081
Death (all-cause) 1.4% (1/70) 3.0% (1/33) .540
CD-TVR 30.0% (21/70) 48.5% (16/33) .081
Major target limb amputation 0.0% (0/70) 0.0% (0/33) > .999
Thrombosis at target lesion site§ 7.1% (5/70) 0.0% (0/33) .174
CD-TLR 25.7% (18/70) 42.4% (14/33) .111
Any TVR 30.0% (21/70) 51.5% (17/33) .049
Any TLR 27.1% (19/70) 48.5% (16/33) .045
Other Major Secondary End Points at 36 Months
Time to first CD-TLR within 1,080 days (d) 293.6 ± 249.5 (18) 314.9 ± 162.7 (14) .783
Primary sustained clinical improvementk 58.5% (38/65) 40.6% (13/32) .131
Secondary sustained clinical improvement¶ 88.5% (54/61) 86.2% (25/29) .741
Change in quality of life from baseline by EQ-5D Index 0.0630 ± 0.2040 (62) 0.0731 ± 0.1864 (28) .825
Change in walking distance from baseline by 6MWT (m) 48.9 ± 115.5 (19) 69.5 ± 70.7 (10) .611
Walking impairment by WIQ (%) 71.4 ± 30.0 (62) 81.9 ± 26.6 (29) .110
Change in ABI/TBI# from baseline to 36 months (ratio mm Hg) 0.163 ± 0.231 (59) 0.141 ± 0.352 (26) .770
Nights in hospital due to index lesion 2.0 ± 3.0 (75) 1.9 ± 2.0 (36) .769
Note–Values are reported as % (n/N) or mean ± SD (N). All events were adjudicated by the independent Clinical Events Committee and
all duplex ultrasound and angiographic measures were made by the independent core laboratories; all other data were site-reported.
6MWT ¼ 6-minute walk test; ABI, ankle-brachial index; CD ¼ clinically driven; EQ-5D ¼ EuroQoL 5-dimension health-related quality-of-
life questionnaire; MAE ¼ major adverse event; PTA ¼ percutaneous transluminal angioplasty; TBI ¼ toe-brachial index; TLR ¼ target
lesion revascularization; TVR ¼ target vessel revascularization; WIQ ¼ Walking Impairment Questionnaire.
*P values are based on Fisher exact test or t test for superiority with significance level of .05.
†Defined as 30-day freedom from device- and procedure-related death and major target limb amputation and 36-month freedom from
CD-TVR.
‡Composite of death, CD-TVR, major target limb amputation, and thrombosis at target lesion site.
§Defined as occlusion because of thrombus formation, confirmed by sudden onset of symptoms and documented by duplex ultra-
sonography and angiography.
kDefined as sustained upward shift of at least 1 category on the Rutherford Clinical Classification scale compared with baseline,
freedom from major target limb amputation, and freedom from TVR.
¶Defined as sustained upward shift of at least 1 category on the Rutherford Clinical Classification scale compared with baseline, and
freedom from major target limb amputation (participants could have had a TVR).
#TBI was not measured in IN.PACT SFA I phase.
Volume 31 ▪ Number 9 ▪ September ▪ 2020 1415using an exit criterion of 0.1. Variables that remained in the
multivariable analysis were reported as hazard ratios with
confidence intervals. For continuous variables, the comparative
direction was incremental for these measured characteristics. A
multivariable analysis for participants treated with PTA could
not be performed owing to small participant numbers. Statistical
analyses were performed using SAS Version 9.4 (SAS Institute,
Inc, Cary, North Carolina).RESULTS
Among participants treated with DCB, women were
significantly older (69.4 y ± 9.9) than men (66.4 y ± 9.1,P ¼ .025) (Table E3 [available online on the article’s
Supplemental Material page at www.jvir.org]). Women had
lower rates of coronary heart disease (47.3% vs 62.1%, P ¼
.043) and renal insufficiency (2.6% vs 11.4%, P ¼ .037).
The mean reference vessel diameter (RVD) was significantly
smaller in women (4.4 mm ± 0.68) compared with men (4.8
mm ± 0.89, P < .001). The remaining baseline character-
istics, including outflow impairment, were not significantly
different between the 2 groups. Percent diameter stenosis
before the procedure was similar between groups, though
directionally smaller in women (79.8% ± 16.2%) compared
with men (81.8% ± 15.2%, P ¼ .356). Diameter stenosis
after the procedure was statistically significantly smaller in
1416 ▪ Outcomes of IN.PACT SFA Trial Through 3 Years by Sex Kohi et al ▪ JVIRwomen (17.8% ± 9.9%) compared with men (21.0% ±
10.5%, P ¼ .028).
The 3-year primary patency rate by Kaplan-Meier esti-
mate following treatment with DCB was 65.4% in women
compared with 71.8% in men (log-rank P ¼ .302) (Fig 2a).
The 3-year freedom from CD-TLR rate by Kaplan-Meier
estimate following DCB was 81.1% in women compared
with 86.4% in men (log-rank P ¼ .285) (Fig 2b).
The primary safety composite of freedom from device-
and procedure-related death through 30 days and freedom
from major target limb amputation and CD-TVR through 36
months was 76.8% in women and 83.6% in men (P ¼ .257)
(Table 1). The rate of major adverse events was 31.9% in
women and 25.8% in men (P ¼ .406). Both groups had a
thrombosis rate of < 3% and no amputations. Women had
a longer length of stay in the hospital compared with men
(2.3 d ± 4.2 vs 1.2 d ± 1.4; P ¼ .026). All-cause mortal-
ity through 3 years was 11.6% in women and 10.2% in men
(P ¼ .810); causes of death are listed in Table E4 (available
online on the article’s Supplemental Material page at www.
jvir.org) (12).
Among participants treated with DCB, predictors of loss
of primary patency through 3 years in women were Trans-
Atlantic Inter-Society Consensus for the Management of
Peripheral Arterial Disease (TASC) C/D lesions and previ-
ous limb amputation; predictors of loss of primary patency
through 3 years in men were longer lesions and shorter total
balloon treatment length (Table 2). Predictors of CD-TLR in
women were previous ipsilateral revascularization, absence
of hyperlipidemia, insulin-dependent diabetes, and
severely calcified lesions; predictors of CD-TLR in men
included higher body mass index and smaller RVDs.
In this trial, 111 participants were treated with PTA (75 men
and 36 women); demographic characteristics are reported in
Table E5 (available online on the article’s Supplemental
Material page at www.jvir.org). Among participants treated
with PTA, women were older (70.4 y ± 8.3) than men (66.9 y
± 9.5, P ¼ .063). Women had a lower body mass index (25.9
± 5.4 vs 27.9 ± 4.4; P ¼ .036) and a higher rate of restenotic
lesions (13.9% vs 1.3%; P ¼ .006). More women had less
severe TASC lesions (80.6% of lesions were TASC A lesions
in women vs 54.5% in men) yet higher Rutherford classes
overall (11.1% of participants were Rutherford Clinical
Classification 4 and 5 in women vs 4.0% in men). The mean
RVD was significantly smaller in women (4.2 mm ± 0.77)
compared with men (4.9 mm ± 0.77, P < .001). The
remaining baseline characteristics, including outflow impair-
ment, were not significantly different between the 2 groups.
Percent diameter stenosis before the procedure was similar
between groups, though directionally smaller in women
(80.1% ± 13.2%) compared with men (81.8% ± 13.9%, P ¼
.535). Diameter stenosis after the procedure was statistically
smaller in women (15.5% ± 8.3%) compared with men
(20.8% ± 10.8%, P ¼ .011).
The 3-year primary patency rate by Kaplan-Meier esti-
mate following treatment with PTA was 42.3% in women
and 46.7% in men (log-rank P ¼ .551) (Fig 3a). The 3-yearfreedom from CD-TLR rate by Kaplan-Meier estimate
following PTA was 59.4% in women and 75.5% in men
(log-rank P ¼ .109) (Fig 3b).
The primary safety composite through 36 months was
51.5% in women and 70.0% in men (P ¼ .081) (Table 3).
The rate of major adverse events was 51.5% in women
and 31.4% in men (P ¼ .081). Women spent a similar
amount of time in the hospital owing to the index lesion
as men (1.9 d ± 2.0 compared with 2.0 d ± 3.0; P ¼
.769). All-cause mortality through 3 years was 3.0% in
women compared with 1.4% in men (P ¼ .540); causes of
death are listed in Table E6 (available online on the article’s
Supplemental Material page at www.jvir.org) (12).DISCUSSION
The reported efficacy and safety of DCBs in women has
been inconsistent, and long-term outcomes have yet to be
reported (Table E7 [available online on the article’s
Supplemental Material page at www.jvir.org]) (13–19). In
the LEVANT 2 trial, superior 1-year patency of a DCB over
PTA was observed in men (70.6% DCB, 48.4% PTA) (16).
However, women appeared to have consistently poorer ef-
ficacy outcomes in both the experimental and the control
arms of LEVANT 2 (56.4% DCB, 61.4% PTA). Interest-
ingly, a subgroup analysis of LEVANT 2 showed contra-
dictory results in the German population: men and women
had similar outcomes. Primary patency at 1 year was 68.0%
in women treated with DCB compared with 42.9% in
women treated with PTA and 76.2% in men treated with
DCB compared with 54.4% in men treated with PTA (17).
In the ILLUMENATE US study of a different DCB plat-
form, men and women benefited equally through 1 year
(men DCB 75.2%, women DCB 77.6%) (9). However, there
were sex-related differences in the ILLUMENATE Global
Registry; women had lower primary patency and freedom
from CD-TLR rates compared with men (male patency
84.5%, female patency 72.8%; male freedom from CD-TLR
96.2%, female freedom from CD-TLR 90.7%) (20). In this
post hoc analysis of the IN.PACT SFA trial, while women
were older and had smaller RVDs, there were no statistically
significant sex-related differences in outcomes observed
through 3 years following treatment with this DCB.
This lack of consistency in efficacy of DCBs in women
suggests that there is no sex-related class effect and that each
DCB platform should be evaluated for effectiveness and
safety by sex. Performance characteristics of the balloon
platforms, variations in the populations in these studies, and
procedural techniques employed in different studies may
contribute to disparate outcomes between men and women.
In the current analysis, women treated with DCB had a
smaller baseline RVD than men treated with DCB, but there
was no statistically significant difference in the 3-year CD-
TLR rates between men and women. Women treated with
DCB spent more time in the hospital than men treated with
DCB; however, reasons for increased hospital stay were not
captured as part of this study. Interestingly, women and men
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primary patency and CD-TLR. While the outcomes may not
have been different, there appears to be a sex-related dif-
ference in PAD comorbidities and predictors of success
following DCB intervention. Whether this DCB platform
nullifies the negative impact of older age and smaller RVD
on outcomes is unclear at this time.
Women treated with PTA also had smaller RVDs, and
also tended to have worse outcomes. In contrast to women
treated with DCB, women treated with PTA had higher rates
of TLR and TVR compared with men treated with PTA.
However, similar to women treated with DCB, Kaplan-
Meier analyses of both patency and freedom from CD-
TLR showed clinically worse, yet not statistically signifi-
cantly worse, outcomes in women.
While all groups had comparable percent diameter ste-
nosis before the procedure, women in both the DCB group
and the PTA group had a statistically significantly smaller
percent diameter stenosis after the procedure compared with
their male counterparts. While this could signal that women
received a better angioplasty during the procedure and this
may have improved their outcomes overall, it is important to
note that percent diameter stenosis is an imperfect way to
extrapolate the increased blood flow that could potentially
affect longer-term results. In this study, men and women had
similar levels of stenosis, but women had smaller vessels;
the volume of blood flowing through women’s vessels was
smaller. After the procedure, even though the percent
diameter stenosis was smaller in women, the minimal lumen
diameter was also smaller: directionally in the PTA group
and reaching statistical significance in the DCB group. As
such, these differences in percent diameter stenosis could be
related more to the generally smaller vessel sizes of women
rather than preferentially better angioplasty. More research
is necessary to understand the interplay of vessel size,
procedural details, and long-term outcomes.
A recent meta-analysis reported a higher risk of mortality
in patients treated with paclitaxel (21); this analysis showed
no difference in mortality between men and women through
3 years. Following this meta-analysis, the Food and Drug
Administration put forth recommendations for inter-
ventionalists as they consider use of DCBs encompassing
patient informed consent and the risk-benefit ratio of all
available PAD treatment options (22). As reported in this
article, women treated with PTA had a higher rate of TLR
and TVR compared with men treated with PTA, and this
higher risk of restenosis should be taken into consideration
when treating women with PAD.
Beyond the endovascular treatment modalities of DCB
and PTA, analysis of the lower extremity arterial revascu-
larization literature reveals that women have increased risks
of 30-day mortality, stroke, early graft thrombosis, ampu-
tation, cardiopulmonary events, embolization, incisional site
complications, and repeat revascularization procedures
(4,23). The evident sex-related disparity in outcomes sug-
gests that additional studies are required to refine and update
understanding of not only how PAD is different in womenand men, but also how to define the differences in responses
to individual treatment modalities. To do so, it is critical to
recruit and retain more women in clinical trials, report
outcomes by sex as standard practice in clinical studies, and
perform meaningful meta-analyses investigating the effects
of sex on outcomes.
This study has several limitations. The relatively small
number of participants followed through 3 years and the low
rate of women included in the trial limit the strength of the
study conclusions; trends and insignificant numerical dif-
ferences observed here may reach significance or become
conclusively nonsignificant in larger patient populations. As
women typically have smaller vessels, device characteris-
tics, such as device diameters, may have influenced partic-
ipant selection and the smaller number of women enrolled in
the study. Stringent inclusion and exclusion criteria of ran-
domized trials may reduce the generalizability of observa-
tions to the population at large.
In conclusion, in the IN.PACT SFA clinical trial, women
with PAD were older and had smaller vessels and trended
toward worse, yet not statistically significantly different,
outcomes following treatment with DCB compared with
men. Women treated with PTA had higher reintervention
rates. Further studies are needed to characterize the differ-
ences in disease progression and outcomes following
endovascular treatment in men compared with women.ACKNOWLEDGMENTS
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t al.
ved in the IN.PACT SFA randomized controlled trial that
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a. True
b. False
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c. Longer lesions
d. A and B
e. A, B, and C
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Table E1. List of Clinical Sites That Enrolled Participants in the IN.PACT SFA Trial
US Clinical Site Location Principal Investigator
Landeskrankenhaus–Universit€atsklinikum Graz Graz, Austria Marianne Brodmann
Inselspital Universit€atsspital Bern Bern, Switzerland Iris Baumgartner
Ospedale Regionale di Lugano Lugano/TI, Switzerland Jos Van den Berg
Imeldaziekenhuis Bonheiden, Belgium Patrick Peeters
AZ Sint-Blasius Dendermonde, Belgium Marc Bosiers
Universitair Ziekenhuis Gent Gent, Belgium Frank Vermassen
Universit€ats-Herzzentrum Freiburg–Bad Krozingen GmbH Bad Krozingen, Germany Thomas Zeller
RoMed Klinikum Rosenheim Rosenheim, Germany Gunnar Tepe
MVZ Prof. Mathey, Prof. Schofer GmbH Hamburg, Germany Sebastian Sixt
Universit€atsklinikum Leipzig A€oR Leipzig, Germany Dierk Scheinert
Universita Cattolica del Sacro Cuore Policlinico Gemelli Roma, Italy Carlo Trani
Clinical Montevergine Mercogliano (AV), Italy Giovanni Sorropago
Maria Eleanora Hospital Palermo, Italy Antonio Micari
US Clinical Site
Cleveland Clinic Cleveland, Ohio Mehdi Shishehbor
Saint Luke’s Episcopal Hospital–Texas Medical Center Houston, Texas Neil Strickman
Hospital of the University of Pennsylvania Philadelphia, Pennsylvania Ronald Fairman
University of Virginia Medical Center Charlottesville, Virginia John Angle
Mount Sinai Medical Center New York, New York Prakash Krishnan
EMH Elyria Medical Center Elyria, Ohio Naim Farhat
Saint Luke’s Hospital Kansas City, Missouri Steven Laster
New York Presbyterian Hospital/Columbia University Medical New York, New York William Gray
Sentara Norfolk General Hospital Norfolk, Virginia Marc Glickman
Washington Hospital Fremont, California Ash Jain
Munroe Regional Medical Center Ocala, Florida Robert Feldman
Mercy Medical Center Des Moines, Iowa David Chew
Arizona Heart Institute Phoenix, Arizona Venkatesh Ramaiah
Abbott Northwestern Hospital Minneapolis, Minnesota Peter Alden
Scripps Green Hospital/Scripps Clinic Torrey Pines La Jolla, California Curtiss Stinis
Banner Good Samaritan Medical Center Phoenix, Arizona Ashish Pershad
Holy Spirit Hospital Camp Hill, Pennsylvania Rajesh Dave
Washington Hospital Center Washington, DC Robert Gallino
Wellmont Holston Valley Medical Center Kingsport, Tennessee Christopher Metzger
Riverside Methodist Hospital Columbus, Ohio Gary Ansel
Deborah Heart and Lung Center Browns Mills, New Jersey Richard Kovach
Saint Vincent Heart Center of Indiana Indianapolis, Indiana Brian Bigelow
University of Kansas Hospital Kansas City, Kansas Kamal Gupta
Mercy Hospital and Medical Center Chicago, Illinois Paul Jones
Beth Israel Deaconess Medical Center Boston, Massachusetts Marc Schermerhorn
The Christ Hospital Cincinnati, Ohio Monica Hunter
The Miriam Hospital Providence, Rhode Island Peter Soukas
Stanford Hospital and Clinics Stanford, California Michael Dake
Saint Francis Hospital Roslyn, New York George Petrossian
Saint Elizabeth’s Medical Center Boston, Massachusetts Lawrence Garcia
WakeMed Health and Hospitals Raleigh, North Carolina Ravish Sachar
Christiana Hospital Newark, Delaware Mark Garcia
Baptist Hospital of Miami Miami, Florida James Benenati
Aurora Saint Luke’s Medical Center Milwaukee, Wisconsin Mark Mewissen
Providence Health Center Waco, Texas Rodney Brown
Arrowhead Hospital Glendale, Arizona Rahul Malhotra
Rex Hospital Raleigh, North Carolina James Zidar
Edward Hospital Naperville, Illinois Mark Goodwin
Terrebonne General Medical Center Houma, Louisiana Craig Walker
continued
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Table E1. List of Clinical Sites That Enrolled Participants in the IN.PACT SFA Trial (continued)
US Clinical Site Location Principal Investigator
Kaiser Permanente—Moanalua Medical Center and Clinic Honolulu, Hawaii Peter Schneider
Pomerado Hospital Poway, California Rod Serry
Longview Regional Medical Center Longview, Texas Samir Germanwala
Advanced Vascular Associated Morristown, New Jersey Amit Patel
University of Pittsburgh Medical Center Passavant Pittsburgh, Pennsylvania Luke Marone
Table E2. Inclusion and Exclusion Criteria
Key Inclusion Criteria
Documented ischemia with Rutherford Clinical Classification 2, 3, or 4
Life expectancy, in the investigator’s opinion, of at least 12 months
Target lesion is in SFA and/or PPA above the knee, located in the arterial segment starting at least 1 cm beyond CFA bifurcation
between superficial and profunda femoris arteries (proximal anatomic landmark) to distal P1 segment of the popliteal artery at the
level of the proximal edge of the patella (distal anatomic landmark)
Angiographic evidence that target lesion consists of single de novo or restenotic lesion without stent (or tandem lesions or a
combination lesion as defined) that is:
 70%–99% occluded with total lesion length  40 mm and  180 mm (by visual estimate); or
 100% occluded with total lesion length  100 mm (by visual estimate)
Key Exclusion Criteria
Contralateral SFA/PPA disease requiring treatment in the same setting as index procedure
Any major (eg, cardiac, peripheral, abdominal) intervention (including in contralateral SFA/PPA) performed within 30 days before
enrollment or planned within 30 days after index procedure
Presence of a second lesion in target vessel that requires treatment but does not meet the definition of tandem lesions
Failure to successfully cross target lesion with guide wire (successful crossing means tip of the crossing device is distal to target
lesion in the absence of flow-limiting dissections or perforations)
Target lesion is an in-stent restenosis or a post-DCB restenosis or has been previously treated with bypass surgery
Dilation before randomization resulted in a major ( grade D) flow-limiting dissection (observed on 2 orthogonal views) or residual
stenosis > 70% and translesional peak gradient > 10 mm Hg
CFA ¼ common femoral artery; DCB ¼ drug-coated balloon; PPA ¼ proximal popliteal artery; SFA ¼ superficial femoral artery.
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Table E3. Baseline Participant and Lesion Characteristics of Participants Treated with DCB
Baseline Participant and Lesion Characteristics Male DCB
(n ¼ 143 participants;
n ¼ 144 lesions)
Female DCB
(n ¼ 77 participants;
n ¼ 77 lesions)
P Value
Baseline Demographics*
Age (y) 66.4 ± 9.1 (143) 69.4 ± 9.9 (77) .025
BMI (kg/m2) 27.6 ± 4.4 (143) 28.1 ± 5.6 (77) .530
Obesity (BMI  30 kg/m2) 23.8% (34/143) 35.1% (27/77) .084
Hypertension 89.5% (128/143) 94.8% (73/77) .217
Hyperlipidemia 84.6% (121/143) 84.4% (65/77) 1.000
Diabetes mellitus 40.6% (58/143) 40.3% (31/77) 1.000
Carotid artery disease 36.8% (49/133) 31.6% (24/76) .456
Coronary heart disease 62.1% (87/140) 47.3% (35/74) .043
Current smoker 41.3% (59/143) 33.8% (26/77) .311
Renal insufficiency (baseline serum creatinine  1.5 ng/dL) 11.4% (16/140) 2.6% (2/77) .037
On dialysis 0.7% (1/140) 0.0% (0/77) 1.000
Below-the-knee vascular disease of target leg (stenotic/
occluded)
39.2% (56/143) 44.2% (34/77) .477
Previous peripheral revascularization 44.8% (64/143) 41.6% (32/77) .671
Previous limb amputation 0.0% (0/143) 2.6% (2/77) .121
Rutherford Clinical Classification .204
0 0.0% (0/143) 0.0% (0/77)
1 0.0% (0/143) 0.0% (0/77)
2 39.2% (56/143) 35.1% (27/77)
3 58.7% (84/143) 54.5% (42/77)
4 2.1% (3/143) 10.4% (8/77)
5 0.0% (0/143) 0.0% (0/77)
6 0.0% (0/143) 0.0% (0/77)
ABI/TBI† (mm Hg ratio) 0.766 ± 0.239 (138) 0.773 ± 0.207 (71) .846
Lesion Characteristics (site-reported)
Outflow impaired 11.9% (17/143) 10.4% (8/77) .826
Lesion type .457
De novo 95.8% (137/143) 93.5% (72/77)
Restenotic (no stent) 4.2% (6/143) 6.5% (5/77)
Number of participants receiving provisional stent 7.0% (10/143) 7.8% (6/77) .828
Lesion Characteristics (core laboratory–reported, per lesion)‡
Vessel§
SFA 96.5% (139/144) 100.0% (77/77) .166
PPA 9.0% (13/144) 2.6% (2/77) .093
Number of run-off vessels occluded
0 39.4% (54/137) 45.3% (34/75) .466
1 45.3% (62/137) 34.7% (26/75) .147
2 12.4% (17/137) 16.0% (12/75) .532
3 2.9% (4/137) 4.0% (3/75) .700
Preprocedure Characteristics
TASC lesion type .595
A 55.6% (80/144) 58.4% (45/77)
B 30.6% (44/144) 31.2% (24/77)
C 13.9% (20/144) 9.1% (7/77)
D 0.0% (0/144) 1.3% (1/77)
RVD (mm) 4.785 ± 0.886 (144) 4.390 ± 0.682 (77) < .001
MLD (mm) 0.900 ± 0.788 (144) 0.900 ± 0.759 (77) .998
Occluded lesion (100% stenosis) 26.4% (38/144) 24.7% (19/77) .872
Diameter stenosis (%) 81.8 ± 15.2 (144) 79.8 ± 16.2 (77) .356
Lesion length (cm) 9.08 ± 4.90 (144) 8.69 ± 4.90 (77) .576
continued
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Table E3. Baseline Participant and Lesion Characteristics of Participants Treated with DCB (continued)
Baseline Participant and Lesion Characteristics Male DCB
(n ¼ 143 participants;
n ¼ 144 lesions)
Female DCB
(n ¼ 77 participants;
n ¼ 77 lesions)
P Value
Postprocedure Characteristics
MLD (mm) 3.999 ± 0.779 (144) 3.724 ± 0.659 (77) .009
Diameter stenosis (%) 21.0 ± 10.5 (144) 17.8 ± 9.9 (77) .028
Acute gain (mm) 3.099 ± 0.960 (144) 2.824 ± 0.794 (77) .033
Note–Values are reported as % (counts/sample size) or mean ± SD (N).
ABI ¼ ankle-brachial index; BMI ¼ body mass index; DCB ¼ drug-coated balloon; MLD ¼ minimum lumen diameter; PPA ¼ proximal
popliteal artery; RVD ¼ reference vessel diameter; SFA ¼ superficial femoral artery; TASC ¼ TransAtlantic Inter-Society Consensus for
the Management of Peripheral Arterial Disease; TBI ¼ toe-brachial index.
*Baseline demographics are site-reported.
†TBI was not measured in IN.PACT SFA I phase.
‡Baseline lesion characteristics are core laboratory–reported. Key core laboratory definitions are as follows:
RVD—angiographic measurement of the normal artery proximal and/or distal to the lesion intended for treatment.
MLD—angiographic measurement of the tightest area of obstruction or stenosis located within the segment of interest or the
intended area of treatment.
Lesion length—angiographic measurement from the proximal healthy vessel segment to the distal healthy vessel segment (eg,
length of obstruction).
§All lesions within artery segment are counted. Note that the number of lesions is greater than the number of participants enrolled, as
2 DCB participants were assessed by sites as having tandem lesions treated during the index procedure and were assessed by the
angiographic core laboratory as having 2 target lesions treated during the index procedure. In addition, 1 DCB participant did not have
a baseline angiogram available for assessment by the angiographic core laboratory.
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Table E4. Kaplan-Meier Estimate of Cause of Death Through 3 Years in Participants Treated with DCB
Cause of Death Male DCB (n ¼ 143 participants) Female DCB (n ¼ 77 participants)
Cardiovascular deaths* 4.5% (6) 4.4% (3)
Acute MI† 0.8% (1) 0.0% (0)
Sudden cardiac death‡ 0.7% (1) 2.9% (2)
Heart failure§ 1.6% (2) 1.5% (1)
Strokek 1.5% (2) 0.0% (0)
Noncardiovascular deaths¶ 4.7% (6) 4.3% (3)
Pulmonary 0.8% (1) 0.0% (0)
Gastrointestinal 0.8% (1) 0.0% (0)
Infection/sepsis (includes inflammatory)* 3.2% (4) 0.0% (0)
Neurologic (noncardiovascular)†† 0.0% (0) 1.5% (1)
Malignancy 0.0% (0) 2.8% (2)
Gastrointestinal 0.0% (0) 1.4% (1)
Bladder 0.0% (0) 1.4% (1)
Undetermined cause‡‡ 0.8% (1) 3.0% (2)
Note–Numbers are Kaplan-Meier estimate (number of participants with event); definitions are from Hicks et al (12).
DCB ¼ drug-coated balloon; MI ¼ myocardial infarction.
*Cardiovascular deaths include acute MI, sudden cardiac death, heart failure, stroke, cardiovascular procedure, cardiovascular
hemorrhage, cardiovascular disease, other cardiovascular causes, and unknown cardiovascular causes.
†Death by any cardiovascular mechanism (eg, arrhythmia, sudden death, heart failure, stroke, pulmonary embolism, peripheral arterial
disease)  30 days after MI, related to the immediate consequence of MI. For simplicity, if a cardiovascular death occurs  30 days of
MI, it will be considered a death due to MI. Death resulting from a procedure to treat MI (percutaneous coronary intervention, coronary
artery bypass graft) or treat complication resulting from MI should also be considered death due to acute MI. Death resulting from
elective coronary procedure to treat myocardial ischemia (chronic stable angina) or death due to MI that is a direct consequence of a
cardiovascular procedure/operation should be considered as death due to cardiovascular procedure.
‡Unexpected death not within 30 days of acute MI death, defined as follows:
Witnessed with or without new or worsening symptoms.
Witnessed within 60 minutes of onset of new or worsening cardiac symptoms (unless symptoms suggest acute MI).
Witnessed and attributed to an identified arrhythmia (captured on electrocardiogram, witnessed on monitor, or unwitnessed but
found on implantable cardioverter defibrillator review).
After unsuccessful resuscitation from cardiac arrest.
After successful resuscitation from cardiac arrest and without identification of specific cardiac or noncardiac etiology.
Unwitnessed in participant seen alive and clinically stable  24 hours before being found without evidence of specific
noncardiovascular cause of death, or if participant was not observed alive within 24 hours of death, undetermined cause of death
should be recorded.
§Clinically worsening symptoms and/or signs of heart failure regardless of heart failure etiology.
kDeath as direct consequence of stroke or complications of stroke.
¶Categories of noncardiovascular deaths include pulmonary, renal, gastrointestinal, pancreatic, hepatobiliary, infection/sepsis (in-
cludes inflammatory), hemorrhage (excluding cardiovascular bleed or stroke), noncardiovascular procedure or surgery, trauma
(including homicide), suicide, neurologic (noncardiovascular), drug reaction or overdose (may include anaphylaxis), other non-
cardiovascular, other noncardiovascular unknown, and malignancies (lung, gastrointestinal, prostate, breast, brain, bone [primary],
undetermined neoplasm, bladder, ovarian, uterine/cervical, renal, sarcoma, hepatic, pancreatic, throat/nasopharyngeal, other).
**For example, systemic inflammatory response syndrome/immune (including autoimmune), may include anaphylaxis from envi-
ronmental antigen (eg, food allergies).
††Excludes cardiovascular death from ischemic stroke, hemorrhagic stroke, or undetermined cause of stroke or cardiovascular
hemorrhage of central nervous system.
‡‡Refers to a death not attributed to one of the above categories of cardiovascular death or to a noncardiovascular cause. Inability to
classify the cause of death may be due to lack of information (eg, the only available information is “patient died”) or when there is
insufficient supporting information or detail to assign the cause of death.
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Table E5. Baseline Participant and Lesion Characteristics of Participants Treated with PTA
Baseline Participant and Lesion Characteristics Male PTA
(n ¼ 75 participants;
n ¼ 77 lesions)
Female PTA
(n ¼ 36 participants;
n ¼ 36 lesions)
P Value
Baseline Demographics*
Age, y 66.9 ± 9.5 (75) 70.4 ± 8.3 (36) .063
BMI, kg/m2 27.9 ± 4.4 (75) 25.9 ± 5.4 (36) .036
Obesity (BMI  30 kg/m2) 26.7% (20/75) 22.2% (8/36) .816
Hypertension 88.0% (66/75) 88.9% (32/36) 1.000
Hyperlipidemia 81.3% (61/75) 83.3% (30/36) 1.000
Diabetes mellitus 53.3% (40/75) 38.9% (14/36) .163
Carotid artery disease 32.3% (21/65) 30.6% (11/36) 1.000
Coronary heart disease 56.8% (42/74) 51.4% (18/35) .682
Current smoker 41.3% (31/75) 25.0% (9/36) .139
Renal insufficiency (baseline serum creatinine  1.5 ng/dL) 8.1% (6/74) 2.9% (1/35) .426
On dialysis 0.0% (0/75) 0.0% (0/36) > .999
Below-the-knee vascular disease of target leg
(stenotic/occluded)
56.0% (42/75) 47.2% (17/36) .421
Previous peripheral revascularization 49.3% (37/75) 52.8% (19/36) .840
Previous limb amputation 4.0% (3/75) 0.0% (0/36) .550
Rutherford Clinical Classification .011
0 0.0% (0/75) 0.0% (0/36)
1 0.0% (0/75) 0.0% (0/36)
2 45.3% (34/75) 22.2% (8/36)
3 50.7% (38/75) 66.7% (24/36)
4 4.0% (3/75) 8.3% (3/36)
5 0.0% (0/75) 2.8% (1/36)
6 0.0% (0/75) 0.0% (0/36)
ABI/TBI† (mm Hg ratio) 0.737 ± 0.190 (72) 0.760 ± 0.187 (34) .557
Lesion Characteristics (site reported)
Outflow impaired 14.9% (11/74) 11.1% (4/36) .770
Lesion type .006
De novo 98.7% (74/75) 86.1% (31/36)
Restenotic (no stent) 1.3% (1/75) 13.9% (5/36)
Number of participants receiving provisional stent 16.0% (12/75) 5.6% (2/36) .121
Lesion Characteristics (angiographic core laboratory–
reported, per lesion)‡
Vessel§
SFA 97.4% (75/77) 88.9% (32/36) .080
PPA 5.2% (4/77) 11.1% (4/36) .263
Number of run-off vessels occluded
0 39.5% (30/76) 27.8% (10/36) .292
1 31.6% (24/76) 36.1% (13/36) .671
2 23.7% (18/76) 33.3% (12/36) .361
3 5.3% (4/76) 2.8% (1/36) 1.000
Preprocedure Characteristics
TASC lesion type .006
A 54.5% (42/77) 80.6% (29/36)
B 31.2% (24/77) 16.7% (6/36)
C 14.3% (11/77) 2.8% (1/36)
D 0.0% (0/77) 0.0% (0/36)
RVD (mm) 4.892 ± 0.771 (77) 4.229 ± 0.770 (36) < .001
MLD (mm) 0.969 ± 0.846 (77) 0.858 ± 0.582 (36) .419
Occluded lesion (100% stenosis) 22.1% (17/77) 13.9% (5/36) .445
Diameter stenosis (%) 81.8 ± 13.9 (77) 80.1 ± 13.2 (36) .535
Lesion length (cm) 9.20 ± 5.22 (77) 7.97 ± 4.86 (36) .233
continued
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Table E5. Baseline Participant and Lesion Characteristics of Participants Treated with PTA (continued)
Baseline Participant and Lesion Characteristics Male PTA
(n ¼ 75 participants;
n ¼ 77 lesions)
Female PTA
(n ¼ 36 participants;
n ¼ 36 lesions)
P Value
Postprocedure Characteristics
MLD (mm) 3.948 ± 0.711 (77) 3.678 ± 0.753 (36) .068
Diameter stenosis (%) 20.8 ± 10.8 (77) 15.5 ± 8.3 (36) .011
Acute gain (mm) 2.979 ± 0.937 (77) 2.820 ± 0.760 (36) .376
Note–Values are reported as % (counts/sample size) or mean ± SD (N).
ABI ¼ ankle-brachial index; BMI ¼ body mass index; MLD ¼ minimum lumen diameter; PPA ¼ proximal popliteal artery; PTA ¼
percutaneous transluminal angioplasty; RVD ¼ reference vessel diameter; SFA ¼ superficial femoral artery; TASC ¼ TransAtlantic
Inter-Society Consensus for the Management of Peripheral Arterial Disease; TBI ¼ toe-brachial index.
*Baseline demographics are site-reported.
†TBI was not measured in IN.PACT SFA I phase.
‡Baseline lesion characteristics are core laboratory–reported. Key core laboratory definitions are as follows:
RVD—angiographic measurement of the normal artery proximal and/or distal to the lesion intended for treatment.
MLD—angiographic measurement of the tightest area of obstruction or stenosis located within the segment of interest or the
intended area of treatment.
Lesion length—angiographic measurement from the proximal healthy vessel segment to the distal healthy vessel segment (eg,
length of obstruction).
§All lesions within artery segment are counted. Note that the number of lesions is greater than the number of participants enrolled, as
2 PTA participants were assessed by sites as having tandem lesions treated during the index procedure and were assessed by the
angiographic core laboratory as having 2 target lesions treated during the index procedure.
Table E6. Kaplan-Meier Estimate of Cause of Death Through 3 Years in Participants Treated with PTA
Cause of Death Male PTA (n ¼ 74 participants) Female PTA (n ¼ 36 participants)
Cardiovascular deaths* 0.0% (0) 0.0% (0)
Noncardiovascular deaths† 1.4% (1) 0.0% (0)
Malignancy 1.4% (1) 0.0% (0)
Gastrointestinal 1.4% (1) 0.0% (0)
Undetermined cause‡ 0.0% (0) 3.0% (1)
Note–Numbers are Kaplan-Meier estimates (number of participants with event); definitions are from Hicks et al (12).
PTA ¼ percutaneous transluminal angioplasty.
*Cardiovascular deaths include acute myocardial infarction, sudden cardiac death, heart failure, stroke, cardiovascular procedure,
cardiovascular hemorrhage, cardiovascular disease, other cardiovascular causes, and unknown cardiovascular causes.
†Categories of noncardiovascular deaths include pulmonary, renal, gastrointestinal, pancreatic, hepatobiliary, infection/sepsis (in-
cludes inflammatory), hemorrhage (excluding cardiovascular bleed or stroke), noncardiovascular procedure or surgery, trauma
(including homicide), suicide, neurologic (noncardiovascular), drug reaction or overdose (may include anaphylaxis), other non-
cardiovascular, other noncardiovascular unknown, and malignancies (lung, gastrointestinal, prostate, breast, brain, bone [primary],
undetermined neoplasm, bladder, ovarian, uterine/cervical, renal, sarcoma, hepatic, pancreatic, throat/nasopharyngeal, other).
‡Refers to a death not attributed to one of the above categories of cardiovascular death or to a noncardiovascular cause. Inability to
classify the cause of death may be due to lack of information (eg, the only available information is “patient died”) or when there is
insufficient supporting information or detail to assign the cause of death.
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Table E7. DCB Outcomes by Sex in Other Trials
Male DCB Male PTA Female
DCB
Female
PTA
Statistical Analyses
THUNDER (13,14)
Cotavance DCB (no longer on the market)
102 total participants from 3 German study centers, enrollment period 2004–2005
Number enrolled 31 (30%) 34 (33%) 17 (17%) 20 (20%) —
LLL at 6 mo 0.42 mm 1.76 mm 0.37 mm 1.61 mm None provided
TLR at 5 y 17% (4/24) 71% (20/28) 38% (6/16) 52% (10/
19)
None provided
PACIFIER (15)
IN.PACT Pacific DCB
91 total participants from 3 German study centers, enrollment period 2010–2011
Number enrolled 26 (28%) 30 (33%) 18 (20%) 17 (19%) —
LLL at 6 mo 0.23 mm
[0.58, 0.12]
0.53 mm [0.18,
0.89]
0.36 mm
[0.10,
0.82]
0.85 mm
[0.58,
1.30]
Men: P ¼ .003
Women: P ¼ .13
TLR at 12 mo 0% [0] 24.1% [7] 16.7% [3] 35.7% [5] Men: P ¼ .012
Women: P ¼ .252
LEVANT 2 (16)
Lutonix DCB
476 total participants from 54 study centers across the globe, enrollment period 2011–2012
Number enrolled 193 (41%) 107 (22%) 123 (26%) 53 (11%) —
Freedom from primary safety
event at 1 y (all)
86.2% (150/174) 84.5% (82/97) 80.4% (90/
112)
67.4% (31/
46)
Men difference ¼ 1.7%
Women difference ¼ 13.0%
Freedom from primary safety
event at 1 y (United States
only)
86.3% (88/102) 85.0% (51/60) 74.4% (58/
78)
80.0% (24/
30)
Men difference ¼ 1.3%
Women difference ¼
-5.6
Primary patency at 1 y (all) 70.6% (115/163) 48.4% (44/91) 56.4% (57/
101)
61.4% (27/
44)
Men difference ¼ 22.2%
Women difference ¼ 4.9%
Primary patency at 1 y (United
States only)
71.9% (69/96) 50.0% (29/58) 50.7% (36/
71)
70.4% (19/
27)
Men difference ¼ 21.9%
Women difference ¼ 19.7%
LEVANT 2 German Substudy (17)
Lutonix DCB
126 total participants from 8 German centers, enrollment period 2011–2012 (476 in full trial)
Total enrolled 50 (40%) 29 (23%) 33 (26%) 14 (11%) —
Primary patency through 395 d 76.2% (32/42) 54.5% (12/22) 68.0% (17/
25)
42.9% (6/
14)
Men difference 21.6%: P ¼ .079
Women difference 25.1%: P ¼ .126
Freedom from TLR through
395 d
93.3% (42/45) 88.5% (23/26) 93.1% (27/
29)
53.8% (7/
13)
Men difference 4.9%: P ¼ .484
Women difference 39.3%: P ¼ .004
Composite safety end point
through 395 d
88.9% (40/45) 80.8% (21/26) 93.1% (27/
29)
38.5% (5/
13)
Men difference 8.1%: P ¼ .060
Women difference 54.6%: P < .001
Lutonix Global SFA (18)
691 total participants from 38 study centers globally, enrollment period 2012–2014
Total enrolled 67.9% (469) — 32.1%
(222)
— —
12-mo TLR-free rate by KM — — 88.9%
(83.9–92.4)
— —
24-mo TLR-free rate by KM — — 85.8%
(80.2–89.8)
— —
Retrospective IN.PACT Registry (19)
IN.PACT Pacific DCB or IN.PACT Admiral DCB
260 total participants, single German center, retrospective analysis of participants treated 2009–2012
Total enrolled 63% (164) — 37% (96) — —
Primary patency at 1 y 83.6 ± 3.0 — 71.6 ± 4.8 — Male vs female: P ¼ .002
Primary patency at 2 y 61.7 ± 4.1 — 39.8 ± 5.6 —
Freedom from TLR at 1 y 88.5 ± 2.4 — 79.9 ± 4.0 — Male vs female: P ¼ .001
Freedom from TLR at 2 y 75.6 ± 3.4 — 55.6 ± 5.5 —
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Table E7. DCB Outcomes by Sex in Other Trials (continued)
Male DCB Male PTA Female
DCB
Female
PTA
Statistical Analyses
ILLUMENATE US (9)
300 total participants from 43 study centers in United States and Austria, enrollment period 2013–2015
Total enrolled 112 (37%) 64 (21%) 88 (29%) 36 (12%) —
Primary patency through 12 mo 75.2% (76/101) 57.4% (35/61) 77.6% (59/
76)
58.1% (18/
31)
—
Primary patency through 12 mo
by KM
80.9 ± 4.0 71.2 ± 6.2 84.1 ± 4.1 70.2 ± 8.0 Log-rank P for difference by sex
through 410 days within DCB cohort:
.4851
CD-TLR at 12 mo 5.7% (6/105) 14.5% (9/62) 10.7% (9/
84)
21.2% (7/
33)
—
ILLUMENATE Global (20)
371 total participants from 37 European/Australia and New Zealand study centers, enrollment period 2013–2015
Total enrollment 271 (73%) — 100 (27%) — —
Primary patency at 365 d by KM 84.5% — 72.8% — Log-rank P ¼ .015
Freedom from CD-TLR through
1 y
96.2% — 90.7% — Log-rank P ¼ .0370
IN.PACT SFA (reported in this study) (5)
331 total participants from 13 European and 44 US study centers, enrollment period 2010–2013
Total enrolled 143 (43%) 75 (23%) 77 (23%) 36 (11%) —
Primary patency through 3 y by
KM
71.8% 46.7% 65.4% 42.3% Male DCB to female DCB: P ¼ .302
Male PTA to female PTA: P ¼ .551
Freedom from CD-TLR through
3 y by KM
86.4% 75.5% 81.1% 59.4% Male DCB to female DCB: P ¼ .285
Male PTA to female PTA: P ¼ .109
Primary safety composite
through 3 y
83.6% 70.0% 76.8% 51.5% Male DCB to female DCB: P ¼ .257
Male PTA to female PTA: P ¼ .081
CD ¼ clinically driven; DCB ¼ drug-coated balloon; KM ¼ Kaplan-Meier; LLL ¼ late lumen loss; PTA ¼ percutaneous transluminal
angioplasty; TLR ¼ target lesion revascularization.
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